Sun X, et al. - Researchers probed the effectiveness and safety of monotherapy or combination therapy of adrenoceptor1 blockers and phosphodiesterase5 inhibitors for treatment. For lower ureteric stones or lower urinary tract symptoms correlated with benign prostatic hyperplasia than monotherapy, combination therapy had the best efficacy of therapy. On International Prostate Symptom Score and Post-Void Residual, Adrenoceptor1 blockers were seen to be more effective than phosphodiesterase5. Findings suggested safety of both monotherapy and combination therapy.